<code id='193F0A8C33'></code><style id='193F0A8C33'></style>
    • <acronym id='193F0A8C33'></acronym>
      <center id='193F0A8C33'><center id='193F0A8C33'><tfoot id='193F0A8C33'></tfoot></center><abbr id='193F0A8C33'><dir id='193F0A8C33'><tfoot id='193F0A8C33'></tfoot><noframes id='193F0A8C33'>

    • <optgroup id='193F0A8C33'><strike id='193F0A8C33'><sup id='193F0A8C33'></sup></strike><code id='193F0A8C33'></code></optgroup>
        1. <b id='193F0A8C33'><label id='193F0A8C33'><select id='193F0A8C33'><dt id='193F0A8C33'><span id='193F0A8C33'></span></dt></select></label></b><u id='193F0A8C33'></u>
          <i id='193F0A8C33'><strike id='193F0A8C33'><tt id='193F0A8C33'><pre id='193F0A8C33'></pre></tt></strike></i>

          
          WSS
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion